Breakthrough in Vaccine 2020 Conference Event Name: 3rd International Conference Vaccines & Vaccination (Vaccine 2020)| May 20-21, 2020 Theme: Advances in Immunology & Vaccine Technology and Their Impact Aim and Scope: Vaccine is a biological preparation that provides active acquired immunity to a particular disease. Immunization currently prevents an estimated 2 to 3 million deaths [….]
MCEDC Interview: Greg Merril, CEO of Adaptive Phage Therapeutics Adaptive Phage Therapeutics’ CEO, Greg Merril, was featured this week in MCEDC’s Built For Bio Video Series. David Petr, CEO of MCEDC, discovers how Greg’s clinical-stage company in Montgomery County, MD is using bacteria phage to combat the worldwide crisis in multi-drug resistant bacterial infections, one [….]
IMAGE CREDIT: https://theperfectpredator.com Adaptive Phage Therapeutics Hosts Book Launch Event for ‘The Perfect Predator’ March 6, 2019 This past weekend marked the launch of ‘The Perfect Predator: A Scientist’s Race to Save Her Husband from a Deadly Superbug: A Memoir’. Adaptive Phage Therapeutics, a clinical stage biotech in Gaithersburg, MD, hosted the event. Some may [….]
BioBuzz has partnered with Wilson Sonsini Goodrich & Rosati for the second installment of the #CEOTalks event series. This event will bring you insights from local company executives on the game-changing technologies they are bringing to market to address one of the greatest public health threats of our age; multi-drug resistant bacteria and other infectious agents. However, bringing [….]
“In Conversation” with Mina Izadjoo, President of IPS In preparation for the upcoming CEO Talks Panel on Innovators Combating Drug Resistance, BioBuzz Contributor, Sarah Ellinwood, Ph.D. caught up with one of the panelists, President and CSO of Integrated Pharma Services (IPS), Dr. Mina Izadjoo for a preliminary “In Conversation” interview. What is your background and [….]
Dr. Carol Nacy, CEO of Sequella, Takes on the Global Crisis of Anti-Microbial Resistance For Dr. Carol Nacy, co-founder and CEO of Rockville, Maryland’s clinical-stage antibiotics developer Sequella, it all started with a fascination for things unseen. “At Catholic University a few wonderful biology professors introduced me to this amazing world of invisible life that [….]
